

Edgar Filing: Aeterna Zentaris Inc. - Form 6-K

AETERNA ZENTARIS

AEterna Zentaris Inc. 1405 du Parc-Technologique Blvd.
Quebec (Quebec) Canada G1P 4P5 T 418 652-8525 F 418 652-0881
www.aeternazentaris.com

PRESS RELEASE
For immediate release

AETERNA ZENTARIS REPORTS 2005 SECOND QUARTER FINANCIAL AND OPERATING RESULTS

ALL AMOUNTS ARE IN CANADIAN DOLLARS

Second quarter 2005 highlights:

Financial

- >> Consolidated revenues of \$74.8 million, compared to \$65.8 million for Q2 2004;
- >> Consolidated R&D expenses of \$7.6 million, compared to \$8.7 million for Q2 2004;
- >> Consolidated earnings from operations of \$4.3 million, compared to \$9.2 million for Q2 2004;
- >> Consolidated net earnings of \$16.4 million, or \$0.36 per share, compared to \$1.3 million, or \$0.03 per share for Q2 2004;
- >> Consolidated cash and short-term position was \$64 million at the end of Q2 2005.

Product development

- >> Ozarelix (D-63153) - Initiation of Phase II trials in hormone-sensitive prostate cancer and benign prostate hyperplasia in Europe;
- >> Ozarelix (D-63153) - Initiation of a Phase I/II trial in hormone-sensitive prostate cancer in the United States;
- >> Perifosine - Disclosure of positive Phase II results in hormone-sensitive prostate cancer;
- >> EP-1572 - Disclosure of positive Phase I results confirming growth hormone secretagogue property.

QUEBEC CITY, CANADA, AUGUST 3, 2005 - AEterna Zentaris Inc. (TSX: AEZ; NASDAQ: AEZS) today reported financial and operating results for the second quarter ended June 30, 2005. Consolidated revenues for the second quarter 2005 were \$74.8 million compared to \$65.8 million for the same period in 2004, an increase of 13.7%. Consolidated R&D expenses net of tax credits amounted to \$7.6 million in the second quarter of 2005 compared to \$8.7

Edgar Filing: Aeterna Zentaris Inc. - Form 6-K

million in the second quarter of 2004, a decrease of 12.6%. Consolidated earnings from operations for the second quarter 2005 were \$4.3 million, compared to \$9.2 million for the second quarter 2004, a decrease of 53.2%. On the other hand, the Company's consolidated net earnings were \$16.4 million, or \$0.36 per basic share and \$0.35 per diluted share for the

AETERNA ZENTARIS

second quarter of 2005 compared to \$1.3 million, or \$0.03 per basic and diluted share for the comparable period in 2004.

The \$9 million increase in consolidated revenues during the second quarter 2005 is attributable to an increase of \$15.1 million revenues from our subsidiary Atrium combined with a decrease of \$6.1 million revenues from our biopharmaceutical segment. This decrease in the biopharmaceutical revenues is all attributable to a \$6.5 million non-recurring milestone payment gained from Solvay Pharmaceuticals in the 2004 second quarter. Net earnings for the second quarter of 2005 include a non-cash and non-recurring gain on dilution of \$20.3 million recorded following the decrease of Aeterna Zentaris' interest in its subsidiary Atrium from 61.1% to 50.1% mainly as a result of Atrium's April 6, 2005 IPO.

As of June 30, 2005, the Company had consolidated cash and short-term investments of \$64 million, including \$46.7 million dedicated to the biopharmaceutical segment. The Company generated consolidated positive cash flow from operating activities of \$4.3 million in the second quarter 2005. The burn rate for the biopharmaceutical segment in the second quarter 2005 was \$3 million as expected.

During the second quarter 2005, the Company continued to advance the product pipeline with the initiation of three new clinical trials in Europe and the United States with ozarelix, the new name for D-63153. Ozarelix is a fourth generation LHRH (Luteinizing Hormone Releasing Hormone) antagonist product administered as a depot formulation. These trials include one Phase II in Europe in hormone-sensitive prostate cancer and another Phase II in Europe in benign prostate hyperplasia, together with a Phase I/II in the United States in hormone-sensitive prostate cancer that was initiated in collaboration with our North American partner Spectrum Pharmaceuticals (NASDAQ: SPPI). Ozarelix (D-63153), which allows for chronic intermittent treatment, could improve clinical symptoms of these diseases while overcoming some of the limitations associated with currently marketed therapies.

Furthermore, our lead signal transduction inhibitor in cancer, perifosine, yielded positive Phase II results in 25 patients suffering from hormone-sensitive prostate cancer. Investigators concluded that perifosine is feasible, well-tolerated and can reduce PSA (Prostatic Specific Antigen) in some patients. Following those results, Phase II trials with perifosine in combination with androgen ablation and chemotherapy are expected to be initiated by our North American partner Keryx Biopharmaceuticals (NASDAQ:KERYX) later this year.

In the field of growth hormone modulators, EP-1572 also yielded positive Phase I results. The study provided clear evidence that this compound is able to induce a significant rise in growth hormone levels after oral administration in healthy volunteers. Potential applications include treatment for growth retardation in children and cachexia associated with chronic disease such as AIDS and cancer. EP-1572, the orally-administered specific growth hormone secretagogue in development, presents a major competitive advantage in terms of ease and convenience of delivery over current treatments which are only

Edgar Filing: Aeterna Zentaris Inc. - Form 6-K

available through injections. Other Phase I clinical trials are currently ongoing to further assess the potential of EP-1572 in growth hormone related disorders.

"At the clinical level, the last quarter was marked by the progress of ozarelix, the new name for D-63153, in prostate cancer and in benign prostate hyperplasia," said Gilles Gagnon, Aeterna Zentaris' President and Chief Executive Officer. "Ozarelix, which we intend to aggressively

AETERNA ZENTARIS

pursue the development over the next year, is now considered as another lead product in our promising LHRH antagonist therapeutic approach, along with cetorelix which is currently in late-stage clinical trials in benign prostate hyperplasia and in endometriosis. As for perifosine, our lead product in the signal transduction inhibitor therapeutic approach, it pursued its progress into further Phase II trials. In addition, we continued to advance other clinical and preclinical products through our pipeline according to our strategic drug development program focused on oncology and endocrinology. In doing so, we feel confident that we are well on our way of developing a deep pipeline of innovative products for the benefit of patients coping with serious diseases while building value for our shareholders," concluded Mr. Gagnon.

Dennis Turpin, Vice President and Chief Financial Officer of Aeterna Zentaris, added, "Our financial position continues to be strong. On a consolidated basis, we remained cash flow positive and our cash and short-term position reached \$64 million as of June 30, 2005. Considering our strong financial position, we will continue to make high-level R&D investments to maintain and grow a broad pipeline of drug development programs with both near-term and long-term potential.

AETERNA ZENTARIS SIX-MONTH CONSOLIDATED FINANCIAL RESULTS

Consolidated revenues for the first half of 2005 increased 21.2% to \$150.7 million, compared to \$124.3 million for the first half of 2004. The Company reported year-to-date 2005 consolidated earnings from operations of \$12.3 million, compared to \$10.8 million for the same period a year earlier. Consolidated net earnings for the first six months of 2005 were \$16.5 million, or \$0.36 per basic and diluted share, compared to a consolidated net loss of \$1.2 million, or \$0.03 per basic and diluted share, for the first six months of 2004.

CONFERENCE CALL INFORMATION

Management will be hosting a conference call for the investment community beginning at 10:00 a.m. Eastern Time today, Wednesday, August 3, to discuss 2005 second quarter financial and operating results and answer questions.

To participate in the live conference call by telephone, please dial 514-807-8791, 416-640-4127 from Canada or 800-814-4941 from outside Canada. Individuals interested in listening to the conference call on the Internet may do so by visiting WWW.AETERNAZENTARIS.COM. A replay will be available on the Company's Web site for 30 days.

ABOUT AETERNA ZENTARIS INC.

Aeterna Zentaris Inc. is an oncology and endocrine therapy focused

Edgar Filing: Aeterna Zentaris Inc. - Form 6-K

biopharmaceutical company with proven expertise in drug discovery, development and marketing. The Company's broad 20 product pipeline leverages six different therapeutic approaches, including LHRH antagonists and signal transduction inhibitors. The lead LHRH antagonist compound, cetrorelix, is currently marketed for IN VITRO fertilization under the brand name Cetrotide(R). Cetrorelix is also in late-stage clinical development for endometriosis and benign prostatic hyperplasia (BPH). The lead signal transduction inhibitor compound, perifosine, is a novel, first-in-class, oral anticancer agent that modulates several key signal transduction pathways, including AKT, MAPK, and JNK that have been shown to be critical for the survival of cancer cells. Perifosine has demonstrated single agent anti-tumor activity in Phase I and Phase II studies and is currently being studied as a

AETERNA ZENTARIS

single agent and in combination with several forms of anti-cancer treatments for various forms of cancer, including non-small cell lung cancer and breast cancer.

Aeterna Zentaris also owns 50.1% of Atrium Biotechnologies Inc. (TSX: ATB.sv), a leading developer, manufacturer and marketer of value-added products for the cosmetics, pharmaceutical, chemical and nutritional industries.

News releases and additional information are available at www.aeternazentaris.com.

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of the Company to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. The Company does not undertake to update these forward-looking statements.

-30-

CONTACTS

MEDIA RELATIONS

Paul Burroughs
(418) 652-8525 ext. 406
paul.burroughs@aeternazentaris.com

INVESTOR RELATIONS

Ginette Vallieres
(418) 652-8525 ext. 265
ginette.vallieres@aeternazentaris.com

Edgar Filing: Aeterna Zentaris Inc. - Form 6-K

EUROPE
 Matthias Seeber
 +49 69 42602 3425
 matthias.seeber@aeternazentaris.com

ATTACHMENT: Financial summary

AETERNA ZENTARIS

(in thousands of Canadian dollars, except share
 and per share data)

CONSOLIDATED RESULTS Unaudited	QUARTERS ENDED JUNE 30,		
	2005	2004	2005
REVENUES	74,828	65,840	15
OPERATING EXPENSES			
Cost of sales	47,958	34,922	9
Selling, general and administrative	12,456	10,712	2
R&D costs, net of tax credits and grants	7,589	8,731	1
Depreciation and amortization	2,500	2,298	
	70,503	56,663	13
Earnings from operations	4,325	9,177	1
Interest income	529	288	
Interest expenses	(3,315)	(2,095)	(
Foreign exchange gain (loss)	(189)	227	
EARNINGS BEFORE THE FOLLOWING ITEMS	1,350	7,597	
Current income taxes	(2,650)	(8,484)	(
Future income taxes	(90)	4,160	(
Gain on dilution	20,253	-	2
Non-controlling interest	(2,459)	(1,943)	(
NET EARNINGS (LOSS) FOR THE PERIOD	16,404	1,330	1
Net earnings (loss) per share			
Basic	0.36	0.03	
Diluted	0.35	0.03	
Weighted average number of shares			
Basic	46,139,814	45,594,326	46,13
Diluted	46,448,125	46,457,409	46,50
Issued and outstanding shares			46,13

Edgar Filing: Aeterna Zentaris Inc. - Form 6-K

CONSOLIDATED BALANCE SHEETS	JUNE 30, 2005
<hr style="border-top: 1px dashed black;"/>	
Cash and short-term investments	6
Other current assets	9
	<hr style="border-top: 1px dashed black;"/>
Long-term assets	16
	21
	<hr style="border-top: 1px dashed black;"/>
Total assets	37
	<hr style="border-top: 1px dashed black;"/>
Current liabilities	9
Deferred revenues	2
Long-term debt	2
Other long-term liabilities	2
Non-controlling interest	6
	<hr style="border-top: 1px dashed black;"/>
Shareholders' equity	23
	13
	<hr style="border-top: 1px dashed black;"/>
Total liabilities and shareholders' equity	37
	<hr style="border-top: 1px dashed black;"/>

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AETERNA ZENTARIS INC.

DATE: AUGUST 3, 2005

By: /s/ Mario Paradis

 Mario Paradis
 Senior Finance Director and
 Corporate Secretary